<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002883</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065190</org_study_id>
    <secondary_id>FRE-FNCLCC-94012</secondary_id>
    <secondary_id>EU-96018</secondary_id>
    <nct_id>NCT00002883</nct_id>
  </id_info>
  <brief_title>Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus</brief_title>
  <official_title>A PROSPECTIVE RANDOMISED TRIAL OF INDUCTION CHEMOTHERAPY WITH 5-FU CONTINUOUS IV INFUSION AND CISPLATIN VERSUS SURGERY IN RESECTABLE ADENOCARCINOMA OF THE LOW THIRD OF THE ESOPHAGUS AND CARDIOESOPHAGEAL JUNCTION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not known whether combining chemotherapy with surgery is more&#xD;
      effective than surgery alone.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without&#xD;
      combination chemotherapy in treating patients with cancer of the esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare survival in patients with operable adenocarcinoma of the lower third of the&#xD;
           esophagus or the cardia treated with fluorouracil/cisplatin vs. no chemotherapy prior to&#xD;
           surgical resection.&#xD;
&#xD;
        -  Assess whether neoadjuvant fluorouracil/cisplatin increases tumor resectability.&#xD;
&#xD;
      OUTLINE: This study is randomized for neoadjuvant chemotherapy. Patients are stratified by&#xD;
      performance status, tumor location, and randomizing center.&#xD;
&#xD;
      Patients randomized to no neoadjuvant chemotherapy undergo resection of the tumor with&#xD;
      adequate margins and resection of regional lymph nodes (R2 with at least 8 nodal groups&#xD;
      recommended).&#xD;
&#xD;
      Patients randomized to neoadjuvant chemotherapy receive fluorouracil and cisplatin at 3-4&#xD;
      week intervals; fluorouracil is given by continuous intravenous infusion for 5 days and&#xD;
      cisplatin is given on the first 2 days of fluorouracil administration. Tumor response is&#xD;
      assessed after 2 courses; responding patients with no serious toxicity receive a third&#xD;
      course. Surgery, as above, is initiated 4-6 weeks after the second or third course of&#xD;
      chemotherapy. Upon recovery (within 3-6 weeks), patients who responded to neoadjuvant&#xD;
      chemotherapy receive 3-4 additional courses of postoperative chemotherapy (maximum total of 6&#xD;
      courses). Patients whose best response was stable disease are assessed for postoperative&#xD;
      radiotherapy.&#xD;
&#xD;
      Patients on either arm with positive resection margins, positive lymph nodes, or equivocal&#xD;
      complete resection are referred for postoperative radiotherapy. Further therapy for patients&#xD;
      with incomplete resection is at the discretion of the physician.&#xD;
&#xD;
      Patients are followed every 3-4 months for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 250 patients will be entered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1996</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Adenocarcinoma of the lower third of the esophagus or the cardia for which complete&#xD;
             resection is feasible&#xD;
&#xD;
               -  Extension to the cardia allowed&#xD;
&#xD;
               -  Cancer of the cardia with extension to the esophagus or stomach allowed&#xD;
&#xD;
                    -  No in situ cancer of the cardia&#xD;
&#xD;
               -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not over 75&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0 or 1&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000&#xD;
&#xD;
          -  Polymorphonuclear lymphocytes greater than 2,000&#xD;
&#xD;
          -  Platelets at least 100,000&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.3 mg/dL (120 micromoles/L)&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No other cardiac contraindication to surgery&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No respiratory contraindication to surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No second malignancy except:&#xD;
&#xD;
          -  Basal cell carcinoma of the skin&#xD;
&#xD;
          -  Adequately treated in situ carcinoma of the uterine cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for tumors of the cardia&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior radiotherapy for tumors of the cardia&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ychou, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4510, 200s, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ychou M, Pignon JP, Lasser P, et al.: Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial. [Abstract] J Clin Oncol 24 (Suppl 18): A-4026, 2006.</citation>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I gastric cancer</keyword>
  <keyword>stage II gastric cancer</keyword>
  <keyword>stage I esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

